Connect® MM- The Multiple Myeloma Disease Registry
Recruiting in Palo Alto (17 mi)
+252 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Celgene
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.
Research Team
BS
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
Inclusion Criteria
I was diagnosed with multiple myeloma less than 2 months ago.
I am part of Cohort 3.
I am starting or planning to start my second treatment for multiple myeloma after the first one stopped working.
See 6 more
Treatment Details
Interventions
- None ()
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Cohort 3: Patients enrolled from 2023Experimental Treatment1 Intervention
Relapsed/Refractory multiple myeloma patients receiving second-line therapy
Group II: Cohort 2: Patients enrolled between December 2012 and mid-2016Experimental Treatment1 Intervention
Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016
Group III: Cohort 1: Patients enrolled between Sep 2009 and Nov 2011Experimental Treatment1 Intervention
Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Celgene
Lead Sponsor
Trials
649
Recruited
130,000+
Top Products
>- **Revlimid (lenalidomide)**: Multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma treatment.
- **Pomalyst (pomalidomide)**: Relapsed/refractory multiple myeloma treatment.
- **Otezla (apremilast)**: Psoriatic arthritis treatment.
- **Thalomid (thalidomide)**: Erythema nodosum leprosum and multiple myeloma treatment.
Jay Backstrom
Celgene
Chief Medical Officer since 2016
MD
Mark Alles
Celgene
Chief Executive Officer since 2016
Bachelor's degree from Lock Haven University of Pennsylvania